别名 ADM、adrenomedullin、AM + [5] |
简介 ADM function is mediated by the CALCRL-RAMP2 and CALCRL-RAMP3 receptor complexes with ADM showing the highest potency for the CALCRL-RAMP2 complex.
Adrenomedullin/ADM and proadrenomedullin N-20 terminal peptide/PAMP are peptide hormones that act as potent hypotensive and vasodilatator agents (PubMed:8387282, PubMed:9620797). Numerous actions have been reported most related to the physiologic control of fluid and electrolyte homeostasis. In the kidney, ADM is diuretic and natriuretic, and both ADM and PAMP inhibit aldosterone secretion by direct adrenal actions. In pituitary gland, both peptides at physiologically relevant doses inhibit basal ACTH secretion. Both peptides appear to act in brain and pituitary gland to facilitate the loss of plasma volume, actions which complement their hypotensive effects in blood vessels. |
靶点 |
作用机制 ADM抑制剂 |
在研机构 |
原研机构 |
在研适应症 |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制 ADM抑制剂 |
在研适应症 |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
靶点 |
作用机制- |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段药物发现 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2022-10-06 |
开始日期2022-03-25 |
申办/合作机构- |
开始日期2019-12-15 |
申办/合作机构- |